Product Details:
| Minimum Order Quantity | 1 Vial |
| Brand | Carbotero 450mg |
| Packaging | 1Vial |
| Dose | 450 mg/45 ml |
| Packaging Size | 45 ml |
| Packaging Type | Glass Bottle |
| Prescription/Non prescription | Prescription |
| Injectable Form | Solution |
| Injection Site | Intravenous |
| Medicine Type | Allopathic |
Additional Information:
Product Details:
| Minimum Order Quantity | 1 Vial |
| Dose/Strength | 1400 mg |
| Composition | GEMCITABINE INJECTION |
| Brand | GEM-RTU 1.4GM |
| Packaging Size | Vial |
| Prescription/Non prescription | Prescription |
| Form | Injection |
| Shelf life | 2 Years |
| Manufacturer | ADLEY |
| Country of Origin | Made in India |
Gemcitabine 1400 mg RTU (Ready-to-Use) Injection is a chemotherapy medication used for the treatment of various solid tumors. It belongs to the class of antimetabolite nucleoside analogs and interferes with DNA synthesis in cancer cells.
Key FeaturesActive Ingredient: Gemcitabine
Strength: 1400 mg
Dosage Form: Ready-to-use solution for injection
Drug Class: Antimetabolite (nucleoside analog)
Route of Administration: Intravenous infusion
Pancreatic cancer (locally advanced or metastatic)
Non-Small Cell Lung Cancer (NSCLC)
Bladder cancer
Breast cancer and other solid tumors, as prescribed
Gemcitabine is incorporated into DNA during replication, causing chain termination and inhibition of DNA synthesis. This leads to apoptosis (cell death) of rapidly dividing cancer cells.
BenefitsEffective against multiple solid tumors
Can be used as monotherapy or in combination chemotherapy regimens
Ready-to-use formulation reduces preparation errors and improves convenience
Administered intravenously under medical supervision
Dose and infusion schedule are determined by body surface area, cancer type, and treatment protocol
Pre-medication and hydration may be required to minimize side effects
Store refrigerated at 2–8°C
Protect from light
Do not freeze
Use immediately after opening/reconstitution
Common side effects: nausea, vomiting, fatigue, low blood counts, fever
Serious risks: myelosuppression, liver enzyme elevation, pulmonary toxicity
Requires close monitoring of blood counts and organ function during treatment
Product Details:
| Strength | 100 mg |
| Form | Injection |
| Packaging Size | 100 mg/Vial |
| Packaging Type | Box |
| Usage | Hospital, Clinical |
| Prescription/Non prescription | Prescription |
| Deals in | Third Party Manufacturing |
Pemetrexed 100 mg Injection is an anticancer (antineoplastic) medication used primarily in the treatment of certain types of lung cancer and mesothelioma. It belongs to the class of drugs known as antifolate chemotherapeutic agents and works by inhibiting cancer cell growth and multiplication.
Key FeaturesActive Ingredient: Pemetrexed
Strength: 100 mg
Drug Class: Antifolate antineoplastic agent
Dosage Form: Lyophilized powder for injection
Route of Administration: Intravenous infusion (after reconstitution)
Non-Small Cell Lung Cancer (NSCLC) – as monotherapy or in combination with other anticancer drugs
Malignant Pleural Mesothelioma – usually in combination with cisplatin
Used as first-line, maintenance, or second-line therapy as prescribed by an oncologist
Pemetrexed inhibits multiple enzymes involved in folate metabolism and DNA synthesis, such as thymidylate synthase and dihydrofolate reductase. This prevents cancer cells from replicating and leads to cell death.
BenefitsEffective against specific lung cancers and mesothelioma
Can be used alone or in combination therapy
Helps slow disease progression and improve survival outcomes
Administered via IV infusion under strict medical supervision
Folic acid and vitamin B12 supplementation is required to reduce treatment-related toxicity
Corticosteroids may be given to minimize skin reactions
Store below 25°C
Protect from light
Reconstituted solution should be used as per medical guidelines
Common side effects include nausea, fatigue, low blood cell counts, and mucositis
Regular blood tests are required to monitor blood counts and kidney function
To be used only under the supervision of a qualified oncologist
Product Details:
| Minimum Order Quantity | 1 Vial |
| Brand | Krabeva 400mg Injection |
| Manufacturer | Biocon |
| Packaging | 1vial |
| Storage | 2 to 8 Degree |
Product Details:
| Minimum Order Quantity | 1 Piece |
| Manufacturer | Alkem |
| Packaging Size | 1 injection |
| Brand | Hersima 440mg |
| Composition | Trastuzumab 440mg |
| Prescription/Non prescription | Prescription |
| Product Name | Hersima 440mg |
| Marketed By | Alkem Pharma |
| Treatment | Cancer |
Product Details:
| Usage | Hospital, Clinical |
| Packaging Size | 100 mg/ 16.7 ml |
| Form of medicine | Injection |
| Application | Anti Cancer |
| Medicine Type | Allopathic |
Additional Information:
Product Details:
| Usage | Clinical, Hospital |
| Prescription/Non prescription | Prescription |
| Deals in | Third Party Manufacturing |
| Medicine Type | Allopathic |
| Application | Anti Cancer |
Additional Information:
Product Details:
| Minimum Order Quantity | 1 Vial |
| Brand | Cytax 260 |
| Composition | Paclitaxel IP 260 mg |
| Manufacturer | Intas Pharmaceuticals |
| Prescription/Non prescription | Prescription |
| Injectable Form | Solution |
| Application | Anti Cancer |
| Packaging Type | Glass Bottle |
| Packaging Size | 260 mg/43.4 ml vial |
| Medicine Type | Allopathic |
| Form | Injection |
Paclitaxel 260 mg Injection is a widely used chemotherapy medication indicated for the treatment of various solid tumors. It belongs to the taxane class of anticancer drugs and acts by disrupting cancer cell division.
Key FeaturesActive Ingredient: Paclitaxel
Strength: 260 mg
Dosage Form: Concentrate for solution for infusion
Drug Class: Taxane (antimicrotubule agent)
Route of Administration: Intravenous infusion
Breast cancer (early-stage and metastatic)
Ovarian cancer
Non-Small Cell Lung Cancer (NSCLC)
AIDS-related Kaposi’s sarcoma
Paclitaxel promotes the assembly of microtubules and stabilizes them against depolymerization. This prevents normal mitotic spindle function, leading to cell cycle arrest and cancer cell death.
BenefitsEffective against multiple solid tumors
Commonly used in combination with other chemotherapy agents
Well-established and clinically proven therapy
Administered only by intravenous infusion under expert medical supervision
Premedication with corticosteroids and antihistamines is required to minimize hypersensitivity reactions
Dose and infusion schedule are determined by the oncologist
Store below 25°C
Protect from light
Do not freeze
Common side effects include alopecia, nausea, vomiting, low blood cell counts, and peripheral neuropathy
Hypersensitivity reactions may occur during infusion
Regular monitoring of blood counts is essential
Additional Information:
Product Details:
| Minimum Order Quantity | 1 Vial |
| Strength | 11.25 mg |
| Brand | Luprova 11.25mg |
| Manufacturer | Celon Labs |
| Prescription/Non prescription | Prescription |
| Composition | Leuprolide depot 11.25 |
| Packaging Size | 1 injection |
| Usage | Clinical,Hospital |
| Form of Medicine | Injection |
Leuprolide Acetate 11.25 mg Depot Injection is a long-acting hormonal therapy used primarily in the management of hormone-sensitive cancers and certain endocrine disorders. It belongs to the class of GnRH (Gonadotropin-Releasing Hormone) agonists.
Key FeaturesActive Ingredient: Leuprolide Acetate
Strength: 11.25 mg (Depot formulation)
Dosage Form: Injectable depot suspension
Drug Class: GnRH agonist
Route of Administration: Intramuscular or subcutaneous injection
Prostate cancer – for androgen deprivation therapy
Breast cancer – hormone-sensitive cases
Endometriosis – management of pain and lesions
Uterine fibroids – to reduce size before surgery
Central precocious puberty (in pediatric use, as prescribed)
Leuprolide Acetate initially stimulates, then suppresses pituitary gonadotropin release. This leads to decreased production of sex hormones—testosterone in men and estrogen in women—thereby slowing hormone-dependent tumor growth or alleviating hormone-related conditions.
BenefitsLong-acting depot formulation allows administration every 3 months, improving convenience and compliance
Reduces disease progression in hormone-sensitive cancers
Helps manage symptoms of endometriosis and fibroids
Administered as intramuscular or subcutaneous depot injection every 3 months
Injection must be given by a healthcare professional
Dose and frequency depend on the condition and patient response
Store refrigerated at 2–8°C
Protect from light
Do not freeze
Common side effects: hot flashes, injection site reactions, mood changes, decreased libido
Long-term use may lead to bone density loss; calcium and vitamin D supplementation may be recommended
Use under strict medical supervision with periodic monitoring
Additional Information:
Product Details:
| Strength | 100 mcg |
| Dose/Strength (ex. 1 mg or 1ml) | 100 mcg/0.50 ml |
| Brand | Cipla |
| Usage/Application | Clinical |
| Application | Anti Cancer |
| Type | Single Use Pre-filled Syringe |
Darbepoetin Alfa 100 mcg Injection is a synthetic erythropoiesis-stimulating agent (ESA) used to treat anemia, particularly in patients with chronic kidney disease or chemotherapy-induced anemia.
Key FeaturesActive Ingredient: Darbepoetin Alfa
Strength: 100 mcg
Dosage Form: Injection
Drug Class: Erythropoiesis-stimulating agent (ESA)
Route of Administration: Subcutaneous or intravenous
Anemia associated with chronic kidney disease (CKD)
Anemia due to chemotherapy in cancer patients
Helps reduce the need for blood transfusions
Darbepoetin Alfa stimulates erythroid progenitor cells in the bone marrow, increasing red blood cell production and improving hemoglobin levels. It has a longer half-life than recombinant human erythropoietin, allowing less frequent dosing.
BenefitsCorrects anemia and reduces symptoms such as fatigue and weakness
Reduces the need for blood transfusions
Longer-acting than traditional erythropoietin, improving patient convenience
Administered via subcutaneous or intravenous injection as prescribed
Dose and frequency depend on hemoglobin levels and patient response
Regular monitoring of hemoglobin and iron status is required
Store refrigerated at 2–8°C
Do not freeze
Protect from light
Common side effects: headache, hypertension, injection site reactions
Serious risks: thromboembolic events, pure red cell aplasia (rare)
Should be used under strict medical supervision with regular blood monitoring
Product Details:
| Packaging Type | Glass Bottle |
| Composition | Ferric Carboxymaltose |
| Usage | Clinical, Hospital |
| Medicine Type | Allopathic |
| Dose/Strength | 1 gm/ 20 ml |
| Packaging Size | 500 mg/10 ml |
Ferric Carboxymaltose Injection (Encicarb 500 mg) is an intravenous iron preparation used to treat iron deficiency and iron deficiency anemia, especially when oral iron is ineffective or not tolerated.
Key FeaturesBrand Name: Encicarb
Active Ingredient: Ferric Carboxymaltose
Strength: 500 mg per vial
Dosage Form: Injection / IV infusion
Drug Class: Parenteral iron replacement therapy
Route of Administration: Intravenous
Iron deficiency anemia due to chronic kidney disease, heavy menstrual bleeding, or malabsorption
Patients intolerant to oral iron therapy
Rapid correction of iron deficiency when immediate replenishment is required
Ferric carboxymaltose provides a stable complex of iron that releases iron slowly into the bloodstream. Iron is then taken up by the bone marrow to support hemoglobin synthesis and red blood cell production.
BenefitsAllows high-dose single administration (up to 500 mg or more per session)
Rapid correction of iron deficiency
Fewer injections compared to traditional iron therapies
Well-tolerated with low risk of gastrointestinal side effects
Administered intravenously under medical supervision
Infusion rate and total dose depend on body weight and hemoglobin levels
Requires monitoring for hypersensitivity during administration
Store below 25°C
Protect from light
Do not freeze
Common side effects: headache, dizziness, nausea, injection site reactions
Rare but serious: hypersensitivity reactions or anaphylaxis
Monitor for signs of iron overload with repeated therapy
Additional Information:
Product Details:
| Minimum Order Quantity | 1 Vial |
| Brand | Celon Labs |
| Usage | Personal, Hospital |
| Packaging Size | 1 Vial |
| Dose | 50 mg/50 ml |
| Prescription/Non prescription | Prescription |
| Form of Medicine | Injection |
| Shelf life | 2Years |
| Form | Injection |
Product Details:
| Strength | 200 mcg |
| Brand | Cipla |
| Dose/Strength (ex. 1 mg or 1ml) | 200 mcg/0.40 ml |
| Usage/Application | Clinical |
| Application | Anti Cancer |
| Type | Single Use Pre-filled Syringe |
Darbepoetin Alfa 200 mcg Injection is a long-acting erythropoiesis-stimulating agent (ESA) used to treat anemia, especially in patients with chronic kidney disease or chemotherapy-induced anemia.
Key FeaturesActive Ingredient: Darbepoetin Alfa
Strength: 200 mcg
Dosage Form: Injection
Drug Class: Erythropoiesis-stimulating agent (ESA)
Route of Administration: Subcutaneous or intravenous
Anemia associated with chronic kidney disease (CKD)
Anemia caused by chemotherapy in cancer patients
Reduces the need for blood transfusions
Darbepoetin Alfa stimulates the erythroid progenitor cells in the bone marrow, increasing red blood cell production and improving hemoglobin levels. Its long half-life allows less frequent dosing compared to traditional erythropoietin.
BenefitsCorrects anemia and alleviates related symptoms like fatigue and weakness
Reduces reliance on blood transfusions
Longer-acting, convenient dosing schedule
Administered via subcutaneous or intravenous injection
Dose and frequency depend on hemoglobin levels, patient condition, and response
Regular monitoring of hemoglobin, iron status, and blood pressure is essential
Store refrigerated at 2–8°C
Do not freeze
Protect from light
Common side effects: headache, injection site reactions, hypertension
Serious risks: thromboembolic events, rare cases of pure red cell aplasia
Must be used under medical supervision with regular monitoring
Additional Information:
Product Details:
| Minimum Order Quantity | 1 Vial |
| Injectable Form | Solution |
| Application | Intravenous |
| Brand | Ifosma 1000mg |
| Manufacturer | Halsted Pharma |
| Packaging Type | Glass Bottle |
| Medicine Type | Allopathic |
| Country of Origin | Made in India |
Additional Information:
Product Details:
| Usage | Hospital, Clinical |
| Prescription/Non prescription | Prescription |
| Form of Medicine | Injection |
| Deals in | Third Party Manufacturing |
| Medicine Type | Allopathic |
| Application | Anti Cancer |
Additional Information:
Product Details:
| Injectable Form | Solution |
| Prescription/Non prescription | Prescription |
| Brand | Cipla |
| Packaging Size | 120 mg/3 ml |
| Medicine Type | Allopathic |
Additional Information:
Product Details:
| Manufacturer | Cipla |
| Usage | Hospital |
| Packaging Size | 100 mg/5 ml |
| Prescription/Non prescription | Prescription |
| Application | Anti Cancer |
| Medicine Type | Allopathic |
Additional Information:
Product Details:
| Brand Name | Fosalon |
| Manufacturer | Celon Labs |
| Packaging Type | vial |
| Usage | Hospital, Clinical |
| Product Type | API |
| Dose | 1 vial Single Dose |
| Packaging Size | 150 mg/vial |
| Medicine Type | Allopathic |
Fosaprepitant Dimeglumine Injection is an antiemetic medication used to prevent chemotherapy-induced nausea and vomiting (CINV). It is a prodrug of aprepitant and belongs to the class of neurokinin-1 (NK1) receptor antagonists.
Key FeaturesActive Ingredient: Fosaprepitant dimeglumine
Drug Class: NK1 receptor antagonist
Dosage Form: Lyophilized powder for injection
Route of Administration: Intravenous infusion
Prevention of acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy
Used in combination with a 5-HT3 receptor antagonist and a corticosteroid
Suitable for adult and selected pediatric patients as prescribed
Fosaprepitant is rapidly converted in the body to aprepitant, which blocks substance P from binding to NK1 receptors in the brain. This helps prevent the vomiting reflex triggered by chemotherapy.
BenefitsProvides effective control of both acute and delayed CINV
Single-dose IV administration improves patient convenience
Enhances overall tolerance of chemotherapy regimens
Administered by IV infusion prior to chemotherapy
Store below 25°C
Reconstituted solution should be used as per clinical guidelines
Common side effects include fatigue, headache, hiccups, and infusion-site reactions
Potential drug interactions with certain chemotherapy agents and steroids
Use only under medical supervision
Additional Information:
Product Details:
| Prescription/Non prescription | Prescription |
| Usage | Hospital, Clinical |
| Packaging Size | 200 mg |
| Form of Medicine | Injection |
| Medicine Type | Allopathic |
| Application | Anti Cancer |
Cyclophosphamide Injection 200 mg is a broad-spectrum anticancer and immunosuppressive medication used in chemotherapy and certain autoimmune conditions. It belongs to the class of alkylating agents (nitrogen mustards) and works by inhibiting the growth and division of rapidly multiplying cells.
Key FeaturesActive Ingredient: Cyclophosphamide
Strength: 200 mg
Dosage Form: Powder for injection (lyophilized)
Drug Class: Alkylating agent
Route of Administration: Intravenous or intramuscular (after reconstitution)
Leukemias and lymphomas (Hodgkin’s and non-Hodgkin’s)
Multiple myeloma
Breast, ovarian, and lung cancers
Autoimmune disorders such as severe rheumatoid arthritis and nephrotic syndrome (as prescribed)
Cyclophosphamide is metabolized in the liver to active compounds that cross-link DNA strands, preventing DNA replication and leading to cancer cell death.
BenefitsEffective against a wide range of cancers
Commonly used in combination chemotherapy regimens
Also useful as an immunosuppressant in selected conditions
Administered only under strict medical supervision
Adequate hydration and supportive care are essential to reduce bladder toxicity
Mesna may be prescribed to prevent hemorrhagic cystitis
Store below 25°C
Protect from light
Reconstituted solution should be used as per clinical guidelines
Common side effects include nausea, vomiting, hair loss, and bone marrow suppression
Risk of hemorrhagic cystitis with high doses
Regular blood counts and kidney function monitoring are required
Product Details:
| Packaging Size | 6 mg/0.6 mL |
| Brand | ABBOT |
| Dose | 1 Single dose Prefilled Syringe of 0.6 mL |
| Injection Site | Subcutaneous |
| Medicine Type | Allopathic |
Pegfilgrastim Injection is a long-acting granulocyte colony-stimulating factor (G-CSF) used to reduce the risk of infection in patients receiving myelosuppressive chemotherapy. It works by stimulating the bone marrow to produce more neutrophils (white blood cells), helping the body fight infections more effectively.
Key FeaturesActive Ingredient: Pegfilgrastim
Drug Class: Long-acting G-CSF (hematopoietic growth factor)
Dosage Form: Sterile solution for injection
Route of Administration: Subcutaneous injection
Prevention of febrile neutropenia in cancer patients undergoing chemotherapy
Helps shorten the duration of neutropenia and lowers infection risk
Used in adults and, in some cases, pediatric patients as prescribed
Pegfilgrastim stimulates the proliferation and differentiation of neutrophil precursors in the bone marrow. The pegylation process prolongs its half-life, allowing once-per-chemotherapy-cycle dosing.
BenefitsLong-acting effect with fewer injections compared to filgrastim
Reduces hospitalization due to infections
Improves patient compliance and convenience
Store refrigerated at 2°C to 8°C
Do not freeze or shake
Protect from light
Common side effects include bone pain, muscle pain, and injection-site reactions
Should be used only under medical supervision
Additional Information:
Product Details:
| Usage | Clinical, Hospital |
| Prescription/Non prescription | Prescription |
| Form | Tablet |
| Deals in | Third Party Manufacturing |
| Medicine Type | Allopathic |
| Application | Anti Cancer |
Additional Information:
Product Details:
| Minimum Order Quantity | 2 Piece |
| Strength | 100 mg |
| Dose/Strength | 100 mg/ 20 ml |
| Company | Celon |
| Packaging Size | Vial |
| Shelf Life | 24 months |
| Manufacturer | CELON |
| Usage | Clinical, Hospital |
| Prescription/Non prescription | Prescription |
| Prescription Type | Prescription |
| Storage | Below 25°C |
| Composition | OXALIPLATIN |
| Brand | Celon Labs,CELDACH |
| Treatment | CRC, CA OVARY |
| Medicine Type | Allopathic |
| Application | Anti Cancer |
Lenalidomide 10 mg Capsule is an oral immunomodulatory anticancer medicine used mainly in the treatment of blood-related cancers.
Key FeaturesActive Ingredient: Lenalidomide
Strength: 10 mg
Dosage Form: Capsule
Drug Class: Immunomodulatory agent (IMiD)
Route: Oral
Multiple Myeloma
Myelodysplastic Syndromes (MDS) with del(5q)
Mantle Cell Lymphoma (as prescribed)
Enhances immune response, inhibits tumor blood vessel formation, and directly induces cancer cell death.
StorageStore below 25°C
Protect from moisture and light
Teratogenic – strict pregnancy prevention required
Regular blood count monitoring needed
Fosaprepitant Dimeglumine Injection is an antiemetic medication used to prevent nausea and vomiting associated with chemotherapy.
Key FeaturesActive Ingredient: Fosaprepitant Dimeglumine
Drug Class: NK1 (Neurokinin-1) receptor antagonist
Dosage Form: Injection
Route: Intravenous
Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
Used in combination with other antiemetics
Blocks substance P at NK1 receptors in the brain, preventing vomiting reflex.
StorageStore below 25°C
Protect from light
Sorafenib 200 mg Tablet is an oral targeted anticancer medicine used for advanced cancers.
Key FeaturesActive Ingredient: Sorafenib
Strength: 200 mg
Dosage Form: Tablet
Drug Class: Multikinase inhibitor
Route: Oral
Hepatocellular carcinoma (liver cancer)
Renal cell carcinoma (kidney cancer)
Differentiated thyroid cancer (in specific cases)
Inhibits tumor cell proliferation and angiogenesis by blocking multiple kinases.
StorageStore below 25°C
Protect from moisture
Fulvestrant 250 mg Injection is a hormonal anticancer medication used in hormone receptor–positive breast cancer.
Key FeaturesActive Ingredient: Fulvestrant
Strength: 250 mg
Dosage Form: Injection
Drug Class: Estrogen receptor antagonist
Route: Intramuscular
Postmenopausal women with ER-positive metastatic breast cancer
Used alone or in combination therapy
Binds to estrogen receptors and accelerates their degradation, blocking estrogen-driven tumor growth.
StorageStore at 2°C–8°C (refrigerated)
Do not freeze
Oxaliplatin 100 mg Injection is a platinum-based chemotherapy drug used primarily in gastrointestinal cancers.